25861 Industrial Boulevard
Solexa is developing DNA sequencing systems for the comprehensive and economical analysis of whole genomes. These systems are intended for use by customers in a wide range of applications from basic research through to the development and implementation of personalized medicine. The amount of information required about individual genomes depends upon the scientific application. Present methods generally provide insufficient information and are costly, which has inhibited progress, for instance in understanding the genetic components of common human diseases and the variable response of individuals to drugs. The systems Solexa is developing are designed to provide very large amounts of information about individual genomes including the entire individual human genomic sequence, and to do so economically.
Solexa was formed by the recent combination of Solexa Limited with Lynx Therapeutics, Inc. Solexa will continue to provide ultra-high volume DNA sequencing services from its Hayward production facility via the Lynx bead-based technology platform until the new fully automated Cluster-SBS instruments begin replacing the older systems later this year and into early 2006. The bead-based systems are mainly used for genome-wide, comprehensive gene expression and small RNA analysis, and the Cluster-SBS technology will enable sequencing services for the broad genome analysis community. Solexa expects to begin placing Cluster-SBS instruments in its production facility and development partner laboratories by the end of this year and to begin broad commercial sale of instruments in early 2006.
Mary L. Schramke
Vice President & General Manager, Genomic Services
Kathy A. San Roman
Vice President, Human Resources & Administration
Thomas J. Vasicek, Ph.D.
Vice President, Business Development
Last Updated: 03-11-05